Analysis for Trinity Biotech
Description & usage
Trinity Biotech develops diagnostic tests and laboratory products for clinical use cases. It benefits from recurring testing demand in specialized diagnostics segments. Key valuation drivers are testing volume, regulatory approvals, product pipeline progress, and cost structure efficiency.
Basic info
- Symbol
- TRIB
- Type
- Stock
- Region
- Europe
- Sector
- Health Care
- Available history
- 11.1 years
- Last trading day
- 04/02/2026
Basic info
- Symbol
- TRIB
- Type
- Stock
- Region
- Europe
- Sector
- Health Care
- Available history
- 11.1 years
- Last trading day
- 04/02/2026
Market context
- DXY
- 120.89
- US 10Y Real
- 1.99%
- Fed Balance
- $6.68T
- EZ HICP
- 2.0%
- ECB Rate
- 4.25%
- Bund 10Y
- 3.03%
- VIX
- 24.54
- HY OAS
- 3.17%
- Brent
- $121.88
- Core HICP
- 2.3%
- DE 2Y
- 2.62%
- EZ PMI
- –
Score overview
The overall score combines Performance, Stability and Trend into one comparable value.
Market context
- DXY
- 120.89
- US 10Y Real
- 1.99%
- Fed Balance
- $6.68T
- EZ HICP
- 2.0%
- ECB Rate
- 4.25%
- Bund 10Y
- 3.03%
- VIX
- 24.54
- HY OAS
- 3.17%
- Brent
- $121.88
- Core HICP
- 2.3%
- DE 2Y
- 2.62%
- EZ PMI
- –
Analysis summary
Technical asset picture
Trinity Biotech (TRIB) currently has a total score of 3 points, placing it in the very weak range. The score is made up of Performance (0), Stability (8) and Trend (5). All three sub-scores are currently below average.
Performance scores 0 points (very weak). Least weak metric: 1Y return at -47.8 %. Main drag: 3Y return at -93.4 %.
Stability scores 8 points (very weak). Least weak metric: Sharpe ratio (90d) at -0.39. Main drag: volatility (365d, annualized) at 109.1 %. That implies very high day-to-day swings. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns-but prices can still fall.
Trend scores 5 points (very weak). Trend signals are mostly negative right now. Least weak metric: trend strength at -0.80. Main drag: Price is about 19.2 % below SMA50.
Overall, the picture is very weak: none of the three dimensions shows a clear strength. On a metric level, Sharpe ratio (90d) stands out, while 3Y return lags.
Current market backdrop
The backdrop currently looks mixed and rather restrictive.
A strong US dollar currently paints a mixed risk picture.
High US real yields and elevated long yields lean toward a restrictive rate backdrop.
What that typically means here
For tech, growth, and communication-services assets, higher real yields and a stronger US dollar typically lean headwind.
Note: DXY is used here as the latest available reading; Euro area PMI was not used actively in the effect logic.
Historical evaluation and qualitative market context only, not investment advice.
Price chart
Use the chart to read recent price behavior before drilling into metrics.
Scores and metrics
Explore the overall score, the three pillar scores, and the metrics behind them.